Sarah Adan

Sarah Adan serves as a key procurement professional within the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, where she manages complex research and technical acquisitions aligned with NIDA’s mission to advance scientific understanding of substance use disorders. She oversees the acquisition of specialized laboratory equipment, clinical research services, and analytical instrumentation critical to neurobiological and behavioral studies. Her portfolio includes high-impact contracts supporting translational research, from preclinical models to clinical trial infrastructure, ensuring that procurement strategies directly enable evidence-based interventions and public health innovation. Adan maintains strategic relationships with leading academic medical institutions including The McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These partnerships reflect a strong emphasis on collaborative, research-driven contracting with elite institutions capable of delivering sophisticated scientific services, including neuroimaging, pharmacokinetic analysis, and behavioral assessment tools. Her contracting patterns prioritize institutional expertise in addiction science, fostering long-term, performance-based engagements that align with NIDA’s research priorities. Her procurement approach is overwhelmingly non-set-aside, with 90.7% of awards issued under full and open competition, indicating a focus on technical merit and scientific capability over socioeconomic preferences. While small business set-asides account for 9.3% of awards, they are selectively applied to ensure competitive innovation without compromising research integrity. Adan’s primary NAICS focus areas include analytical laboratory instrument manufacturing (334516) and testing laboratory services (541380), reflecting her specialization in procuring precision equipment for drug metabolism analysis, biomarker detection, and neurochemical monitoring. She also frequently acquires scientific consulting services (541690) and maintenance for electromedical devices (334510), underscoring her deep technical expertise in supporting high-complexity, federally funded addiction research initiatives.